befotertinib   Click here for help

GtoPdb Ligand ID: 12951

Synonyms: compound 4 [WO2019218987A1] [2] | D-0316 | D0316 | Surmana®
Approved drug
befotertinib is an approved drug (China NMPA (2023))
Compound class: Synthetic organic
Comment: Befotertinib (D-0316) is an third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that was developed as a treatment for non-small cell lung cancer (NSCLC) [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 13
Topological polar surface area 84.8
Molecular weight 567.61
XLogP 3.32
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES C=CC(=O)NC1=C(C=C(C(=C1)NC2=NC=CC(=N2)C3=CN(CC(F)(F)F)C4=C3C=CC=C4)OC)N(C)CCN(C)C
InChI InChI=1S/C29H32F3N7O2/c1-6-27(40)34-22-15-23(26(41-5)16-25(22)38(4)14-13-37(2)3)36-28-33-12-11-21(35-28)20-17-39(18-29(30,31)32)24-10-8-7-9-19(20)24/h6-12,15-17H,1,13-14,18H2,2-5H3,(H,34,40)(H,33,35,36)
Classification Click here for help
Compound class Synthetic organic
Approved drug? Yes (China NMPA (2023))
IUPAC Name Click here for help
International Nonproprietary Names Click here for help
INN number INN
11357 befotertinib
Synonyms Click here for help
compound 4 [WO2019218987A1] [2] | D-0316 | D0316 | Surmana®
Database Links Click here for help
CAS Registry No. 1835667-63-4 (source: WHO INN record)
ChEMBL Ligand CHEMBL5095167
GtoPdb PubChem SID 485206072
PubChem CID 130412842
Search Google for chemical match using the InChIKey USOCZVZOXKTJTI-UHFFFAOYSA-N
Search Google for chemicals with the same backbone USOCZVZOXKTJTI
Search PubMed clinical trials befotertinib
Search PubMed titles befotertinib
Search PubMed titles/abstracts befotertinib
UniChem Compound Search for chemical match using the InChIKey USOCZVZOXKTJTI-UHFFFAOYSA-N
UniChem Connectivity Search for chemical match using the InChIKey USOCZVZOXKTJTI-UHFFFAOYSA-N